



PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

Approved for use through 10/31/2002 GMB 0031-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Shee

of 3

<i>Complete if Known</i>	
Application Number	10/790,562
Filing Date	March 1, 2004
First Named Inventor	Hatboer et al. Bout et al.
Group Art Unit	1636
Examiner Name	W. Schlapkohl
Attorney Docket Number	2578-4038.3US

## U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
WS		WO 95/05465	02-23-1995	Amgen Inc.		
		WO 98/18926	05-07-1998	G.D. Searle & Co.		
		WO 98/39411	09-11-1998	Baxter International Inc.		
		WO 98/44141	10-08-1998	The University of British Columbia		
		WO 99/05268	02-04-1999	Boehringer Mannheim GMBH		
		WO 00/61164	10-19-2000	Kenneth S. Warren Laboratories		
		WO 00/63403	10-26-2000	Introgenue B.V.		
		WO 01/38362 A2	05-31-2001	Crucell Holland B.V.		
		WO 02/053580	07-11-2002	The Kenneth S. Warren Institute, Inc.		
		WO 03/038100 A1	05-08-2003	Crucell Holland B.V.		
		WO 03/048197 A1	06-12-2003	Crucell Holland B.V.		
		WO 03/048348 A2	06-12-2003	Crucell Holland B.V.		
		WO 03/051927	06-26-2003	Crucell Holland B.V.		
▼		WO 2004/003176	01-08-2004	The Kenneth S. Warren Institute, Inc.		
		WO 2004/099396	11-18-2004	Crucell Holland B.V.		
WS		EP 0 411 678	02-06-1991	Genetics Institute, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of 3

*Complete if Known*

Application Number	10/790,562
Filing Date	March 1, 2004
First Named Inventor	Hatobec et al. Bout et al.
Group Art Unit	1636
Examiner Name	W. Schlapkohl
Attorney Docket Number	2578-4038 3US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
WS		BOUT et al., "Improved helper cells for RCA-free production of E1-deleted recombinant adenovirus vectors," <i>Cancer Gene Therapy</i> , 1996, pp. S24, Vol. 3, No. 6.	
		BOUT et al., "Production of RCA-free batches of E1-deleted recombinant adenoviral vectors on PER.C6," <i>Nucleic Acids Symp. Ser.</i> 1998, XP-002115716, pp. 35-36.	
		BOUTL et al., "A novel packaging cell line (PER.C6) for efficient production of RCA-free batches of E1-deleted recombinant adenoviral vectors," <i>Cancer Gene Therapy</i> , 1997, pp. S32-S33, Vol. 4, No. 6.	
		CARROLL et al., Abstract, Differential Infection of Receptor-modified Host Cells by Receptor-Specific Influenza Viruses, <i>Virus Research</i> , Sep. 1985, pp. 165-79, Vol. 3, No. 2.	
		CRONAN, Abstract, Biotinylation of Proteins in-vivo a post-translational modification to label purify and study proteins, <i>Journal of Biological Chemistry</i> , June 25, 1990, pp. 10327-33, Vol. 265, No. 18.	
		European Search Report 05 10 0732, April 7, 2005.	
		FALLAUX et al., "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses," <i>Human Gene Therapy</i> , Sept. 1, 1998, Vol. 9, No. 1, pp. 1909-1917. Abstract.	
		GRABENHORST et al., Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(beta-1-4)GlcNAc-R alpha-2,6-sialyltransferase alpha-2,6-Linked NeuAc is preferentially attached to the Gal(beta-1-4)GlcNAc(beta-1-2)Man(alpha-1-3)-branch of diantennary oligosaccharides from secreted recombinant beta-trace protein, <i>Eur. J. Biochem.</i> 1995, pp. 718-25, Vol. 232, No. 3, Berlin, Germany.	
		GRAND et al., "Modulation of the level of expression of cellular genes in adenovirus 12-infected and transformed human cells," <i>Eur Mol Biol Organ J.</i> 1986, 5 (6) 1253-1260. Abstract.	
		GRAND et al., "The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression," <i>Virology</i> , 1995, Vol. 210, No. 2, pp. 323-334. Abstract.	
		HOLLISTER et al., Stable expression of mammalian beta1,4-galactosyltransferase extends the N-glycosylation pathway in insect cells, <i>Glycobiology</i> , 1998, pp. 473-80, Vol. 8, No. 5, IRL Press, United Kingdom.	
▼		JENKINS et al., Getting the glycosylation right: Implications for the biotechnology industry, <i>Nature Biotechnology</i> , August 1996, pp. 975-81, Vol. 14, No. 8, Nature Publishing, US.	
WS		LOUIS et al., Cloning and Sequencing of the Cellular-Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line, <i>Virology</i> , 1997, pp. 423-29, Vol. 233.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

*Complete if Known*

Application Number	10/790,562
Filing Date	March 1, 2004
First Named Inventor	Hatobuci et al. Bout et al.
Group Art Unit	1636
Examiner Name	W. Schlapkohl
Attorney Docket Number	2578-4038 31US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
WS		MINCH et al., Tissue Plasminogen Activator Coexpressed in Chinese Hamster Ovary Cells with alpha(2,6)-Sialyltransferase Contains NeuAc-alpha(2,6)Gal-beta(1,4)Glc-N-Acr Linkages, Biotechnol. Prog., 1995, pp. 348-51, Vol. 11, No. 3.	
		PACITTI et al., Inhibition of Reovirus Type 3 Binding to Host Cells by Sialylated Glycoproteins Is Mediated through the Viral Attachment Protein, Journal of Virology, May 1987, pp. 1407-15, Vol. 61, No. 5, American Society for Microbiology.	
		PAU et al., Abstract, The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines, Vaccine, Mar. 21, 2001, pp. 2716-21, Vol. 19, No. 17-19.	
		PAZUR et al., Abstract, Oligosaccharides as immunodeterminants of erythropoietin for two sets of anti-carbohydrate antibodies, Journal of Protein Chemistry, November 2000, pp. 631-35, Vol. 19, No. 8.	
		SCHIEDNER et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production, 2000, Hum. Gene Ther. 11, 2105-2116.	
		STOCKWELL et al., High-throughput screening of small molecules in Miniaturized Mammalian Cell-based Assays involving Post-translational Modifications, Chemistry and Biology, February 1999, pp. 71-83, Vol. 6, No. 2.	
		WEIKERT et al., Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins, Nature Biotechnology, November 1999, pp. 1116-21, Vol. 17, No. 11, Nature Pub. Co., New York, NY, US.	
WS		YU et al., "Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A," Cancer Res., 1993, 53 (4) 891-8. Abstract.	
WS		ZHANG et al., Stable expression of human alpha-2,6-sialyltransferase in Chinese hamster ovary cells: functional consequences for human erythropoietin expression and bioactivity, BBA - General Subjects, 1998, pp. 441-52, Vol. 1425, No. 3, Elsevier Science Publishers, NL.	

Examiner Signature	/Walter Schlapkohl/	Date Considered	1/11/07
--------------------	---------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231